Page Banner
Mayo Clinic Laboratories > Hematology > Myeloid neoplasms

Myeloid neoplasms

Identifying abnormalities to guide prognosis and treatment

The diagnosis and treatment of leukemias can be highly complex, which is why clinicians need a complete picture before proceeding with a course of treatment. Our leukemia test menu includes flow cytometry, chromosome, FISH, and molecular testing. We provide accurate results and expert interpretation from a highly focused team of laboratory specialists.

Acute myeloid leukemia Acute myeloid leukemia
Acute myeloid leukemia

Our clinically validated testing for acute myeloid leukemia can provide critical diagnostic, prognostic, and therapeutic information for physicians.

Children’s Oncology Group Children’s Oncology Group
Children’s Oncology Group

Our Cytogenetics Laboratory is one of the longest-standing Children’s Oncology Group (COG)-approved laboratories in the world. Our team is committed to meeting the specific needs of COG patients and has developed one of the largest COG-specific testing menus to do just that.

Eosinophilia Eosinophilia
Eosinophilia

Our suite of fluorescence in situ hybridization tests is designed to identify malignancies in select genes associated with eosinophilia.

Myelodysplastic syndrome Myelodysplastic syndrome
Myelodysplastic syndrome

Our approach to myelodysplastic syndrome (MDS) testing utilizes comprehensive fluorescence in situ hybridization (FISH) panels to detect for genetic biomarkers associated with disease severity, progression, and treatment response.

Myeloproliferative neoplasms Myeloproliferative neoplasms
Myeloproliferative neoplasms

The four classic myeloproliferative neoplasms include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

VEXAS syndrome VEXAS syndrome
VEXAS syndrome

UBA1Q is a quantitative droplet digital polymerase chain reaction (ddPCR) assay that targets seven possible mutations that can occur in the UBA1 gene and help identify VEXAS syndrome.

News and updates

The latest

Personalized pathways through digital diagnostics: A Q&A with Chris Garcia, M.D. featured image
Personalized pathways through digital diagnostics: A Q&A with Chris Garcia, M.D.

Christopher Garcia, M.D., shares how secure digital tools, wearable data, and AI can enable more personalized diagnostic pathways, while still keeping clinicians in the driver’s seat.

Learn more
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Mayo Clinic-developed mass spectrometry assay improves detection of monoclonal proteins, advancing outcomes in hard-to-treat diseases

The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.

Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization

The diagnosis of Myeloproliferative Neoplasm (MPN) must include an integrated approach and combine the clinical findings with laboratory results. In our latest “Hot Topic,” Rong He, M.D., discusses the subclassification of MPNs and the use of JAK2, CALR, and MPL mutational analysis in diagnosis and prognosis.

Myeloid Blast and Maturation Assessment by Flow Cytometry (“MDS Flow”)

Flow cytometric immunophenotyping method can be useful in assessing myeloid dysmaturation. In this “Hot Topic,” Dragon Jevremovic, M.D., Ph.D., describes a new flow cytometric test to detect aberrant patterns of expression in the diagnosis of myelodysplastic syndrome.

(BETA) Choose a language to view this content in:
About the translation.